Related Experiment Video

Updated: May 15, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

New agents on the horizon in hepatocellular carcinoma

Andrew X Zhu1

  • 1Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, LH/POB 232, Boston, MA 02114, USA.

Therapeutic Advances in Medical Oncology
|January 17, 2013
PubMed

Insights

Despite sorafenib use, advanced hepatocellular carcinoma (HCC) patients have a poor prognosis. This review examines new molecularly targeted agents for HCC, noting challenges in drug development despite early promising results.

Area of Science:

  • Hepatocellular Carcinoma Research
  • Molecularly Targeted Therapies
  • Oncology Drug Development

Background:

  • Sorafenib is approved for advanced hepatocellular carcinoma (HCC), but patient prognosis remains poor.
  • Despite sorafenib's use, significant research is ongoing for novel molecularly targeted agents in HCC.
  • Challenges exist in developing new drugs for HCC, as evidenced by mixed results in clinical trials.

Purpose of the Study:

  • To review the current development status of molecularly targeted agents for advanced HCC.
  • To summarize early-phase and late-phase clinical trial findings for new HCC therapies.
  • To highlight the challenges and progress in targeted therapy research for HCC.

Main Methods:

  • Literature review of ongoing research and clinical trials.
  • Analysis of phase I, II, and III study outcomes for targeted agents in HCC.
  • Synthesis of data on antitumor activity and development challenges.

Main Results:

  • Several targeted agents show early evidence of antitumor activity in phase I/II studies.
  • Phase III trials for some targeted agents have unfortunately failed to meet endpoints.
  • The development landscape for advanced HCC targeted therapies is complex and challenging.

Conclusions:

  • New molecularly targeted agents are under investigation for advanced HCC.
  • Clinical trial outcomes underscore the difficulties in bringing new HCC drugs to market.
  • Continued research is crucial for improving treatment options for advanced HCC patients.
Keywords:
EGFR inhibitorsMet inhibitorsbevacizumabbrivanibeverolimushepatocellular carcinomalinifanibsorafenibsunitinibtargeted agents

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...